



NATIONAL QUALITY FORUM

Driving measurable health
improvements together

Memo

August 27, 2021

To: NQF members

From: NQF staff

Re: Cardiovascular Spring 2021 Cycle Draft Report for Review

Background

This report reflects the review of measures in the Cardiovascular project. In the spring 2021 cycle of this project, the 25-person Cardiovascular Standing Committee met in-person to review two new measures against NQF's standard evaluation criteria. Both measures were recommended for endorsement.

Recommended Measures:

- NQF #3610 30-Day Risk-Standardized Morbidity and Mortality Composite Following Transcatheter Aortic Valve Replacement (TAVR) (American College of Cardiology [ACC])
- NQF #3613e Appropriate Treatment for ST-Segment Elevation Myocardial Infarction (STEMI) Patients in the Emergency Department (ED) (Centers for Medicare & Medicaid Services [CMS]/Yale Center for Outcomes Research & Evaluation [CORE])

The Standing Committee requests comments on all measures, but specifically for the measures where consensus was not reached.

NQF Member and Public Commenting

NQF members and the public are encouraged to provide comments via the online commenting tool on the draft report as a whole or on the specific measures evaluated by the Cardiovascular Standing Committee.

Please note that commenting concludes on September 27, 2021, at 6:00 PM ET—no exceptions.